Form 4: Regeneron Director Arthur F. Ryan Disposes of Shares Under 10b5-1 Plan

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Arthur F. Ryan, a director of Regeneron Pharmaceuticals, Inc., reported the disposition of company stock on April 1, 2024.
• The transactions were executed under a pre-arranged trading plan compliant with Rule 10b5-1(c), which was adopted on August 7, 2023.
• A total of 98 shares of common stock were sold at various prices ranging from $957.78 to $965.82.
• Following these transactions, Ryan directly owns 18,182 shares of Regeneron common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by a company director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on material non-public information. The use of a 10b5-1 plan provides a legal framework for insiders to sell shares over a period of time.

Comparison to Industry Standards

• Director stock sales are a normal part of corporate governance.
• The 10b5-1 trading plan is a common tool used by corporate insiders to diversify their holdings and manage personal finances while avoiding accusations of insider trading.
• Similar sales are regularly seen at companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB).

Stakeholder Impact

• The stock sale is unlikely to have a significant impact on shareholders, as it was conducted under a pre-arranged trading plan.

Key Dates